FDA Approval of Eli Lilly’s Tirzepatide Weighs on Competitors
Daniel Barasa sits down with GabelliTV to provide the skinny on Eli Lilly’s Tirzepatide weight loss drug and its recent FDA Approval. To learn more about Gabelli Funds’ disciplined, research driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com. Connect with Gabelli Funds: • Twitter – https://twitter.com/InvestGabelli • Instagram – https://www.instagram.com/investgabelli/ • Facebook – https://www.facebook.com/InvestGabelli […]
Revolutionizing Healthcare: The $100 Billion Future of Weight Loss Drugs
Jeff Jonas sits down with GabelliTV and gives the latest scoop on the Future of Weight Loss Drugs. To learn more about Gabelli Funds’ disciplined, research driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com. Connect with Gabelli Funds: • Twitter – https://twitter.com/InvestGabelli • Instagram – https://www.instagram.com/investgabelli/ • Facebook – https://www.facebook.com/InvestGabelli • LinkedIn – https://www.linkedin.com/company/investgabelli/ […]